India Business Excellence Fund III Trims Molbio Diagnostics Stake

Shares Sold: 23,77,627
Post-Sale Holding: 6.85%

Reader Takeaway: Institutional selling increases circulating stock, though the fund maintains a significant 6.85% residual stake in the firm.

What just happened

India Business Excellence Fund III has sold 23,77,627 shares of Molbio Diagnostics, representing a 2.06% equity stake. The transaction took place on September 30, 2026, through an open market sale. Following this disposal, the fund’s total shareholding in the company has decreased from 1,02,76,750 shares (8.92%) to 78,99,123 shares (6.85%).

Why this matters

The sale is a notable movement of institutional capital within the firm. Under SEBI regulations, this divestment was disclosed because it crossed the mandatory 2% threshold for change in shareholding. For retail investors, large open market sales by private equity funds can temporarily increase selling pressure on the stock.

What changes now

With the fund’s exposure dropping below 7%, market participants will watch to see if this is part of a larger phased exit strategy or a rebalancing of the fund's portfolio. No further comments were provided by the fund regarding their future plans for the remaining 6.85% stake.

What to track next

Investors should monitor the company's subsequent shareholding pattern filings to see if the fund continues to offload its remaining position or holds steady in the coming quarters.